SCFA supplementation to HD patients can alleviate pro-inflammatory parameters with a decline of CRP, IL-2, IL-6, IL-17, and interferon-ƴ and increase in anti-inflammatory IL-10 [6]. This evidence concerns the gene IL17A and Huntington disease.